The page below is a sample from the LabCE course Breast Cancer Predictive Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Breast Cancer Predictive Markers (online CE course) »
How to Subscribe
Histology CE Package$65 Add to cart
Individual course$20 Add to cart

Response Rates to Targeted Therapy

Research data has shown that tamoxifen therapy prolonged both disease-free periods and also overall survival rates in patients with estrogen receptor (ER)-positive breast tumors, but had little benefit for patients who had ER-negative tumors. In addition, patients who were ER-negative, but progesterone receptor (PR)-positive, also improved with tamoxifen therapy.